This review looked at several studies comparing GLP-1 receptor agonists to a placebo for people with Parkinsons disease. The main goal was to see if these drugs helped with movement problems or other symptoms. Researchers measured how well patients moved in both on and off medication states at different times during the trials.
The results showed that patients taking GLP-1 drugs had a tiny improvement in quality of life scores. However, there was no real difference in how well patients moved or handled daily tasks. The drugs did not change the course of the disease or stop it from getting worse.
Safety was also checked during the review. Patients taking GLP-1 drugs reported more stomach problems like nausea and vomiting. Because these side effects were common, doctors must weigh the small benefits against the risks before suggesting these medicines for Parkinsons disease.